Sarin R, Khandrika L, Hanitha Rnm, Avula A, Batra M, Kaul S, Raj H, Shivkumar S, Gupta S, Khan E, Bhandari Tps, Prasad Svss, Reddy V A, Swarnalata G, Bakre M, Chatterjee S, Jain J
Indraprastha Apollo Hospitals, New Delhi, India.
Sapien Biosciences Pvt. Ltd., Hyderabad, Telangana, India.
Indian J Cancer. 2016 Jul-Sep;53(3):353-359. doi: 10.4103/0019-509X.200682.
This is a retrospective study with data collected from breast cancer cases from five major Apollo Hospitals across India, as part of a biobanking process. One aspect of our study focused specifically on data from triple-negative breast cancer (TNBC) cases. The aim of this study was to analyze epidemiology, treatment options, and survival of the patients with TNBC. Our goal was to draw conclusions on the preponderance of the disease and also to understand the outcomes using the existing therapy options.
Data were collected after due ethical clearances and were coded with regard to patient identifiers to protect patient privacy. Data were not only from the various departments of the respective hospitals and the treating physicians but also from the follow-up made by hospital staff and social workers.
About 20% of all cases of breast cancer comprised TNBC. Although the disease is generally thought to be an early onset disease, there was no major difference in the median age of diagnosis of TNBC compared to other breast cancer cases. More than 85% of the TNBC cases were of early stage disease with <4% of the cases of metastatic cancer. Data on follow-up were somewhat sporadic as a good number of cases were lost to follow-up, but from the available data, recurrence rate was about 11%. Death, when it occurred, was mostly in the early periods of treatment with 35% of the events occurring before 3 years. The overall survival rates beyond 3 years were more than 86%.
Data and sample collection are an ongoing process, so we expect this data set to be enriched with more cases and longer duration of follow-up in a year. Preliminary analysis sheds light on the potential of such a collection both for understanding the epidemiology of the disease and also for conducting future studies with an eye toward improving treatment outcomes.
这是一项回顾性研究，收集了印度五家主要阿波罗医院乳腺癌病例的数据，作为生物样本库工作的一部分。我们研究的一个方面特别关注三阴性乳腺癌（TNBC）病例的数据。本研究的目的是分析TNBC患者的流行病学、治疗选择和生存率。我们的目标是得出关于该疾病优势情况的结论，并了解使用现有治疗方案的结果。
在获得适当的伦理批准后收集数据，并对患者标识符进行编码以保护患者隐私。数据不仅来自各医院的不同科室和主治医生，还来自医院工作人员和社会工作者的随访。
所有乳腺癌病例中约20%为TNBC。尽管一般认为该疾病是一种早发性疾病，但TNBC的诊断中位年龄与其他乳腺癌病例相比没有显著差异。超过85%的TNBC病例为早期疾病，转移性癌症病例占比不到4%。随访数据有些零散，因为大量病例失访，但从现有数据来看，复发率约为11%。死亡情况大多发生在治疗早期，35%的死亡事件发生在3年之前。3年以上的总生存率超过86%。
数据和样本收集是一个持续的过程，因此我们预计该数据集在一年内会因更多病例和更长随访时间而更加丰富。初步分析揭示了这样一个数据集在了解疾病流行病学以及开展旨在改善治疗结果的未来研究方面的潜力。
